Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin
about
ASARM peptides: PHEX-dependent and -independent regulation of serum phosphateDegradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYPRegulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathwayA unified model for bone-renal mineral and energy metabolismProteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemiaRecent advances in the renal-skeletal-gut axis that controls phosphate homeostasisMEPE is a novel regulator of growth plate cartilage mineralizationPHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolismAbnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator.FGF-23 in bone biology.Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.The impairment of osteogenesis in bone sialoprotein (BSP) knockout calvaria cell cultures is cell density dependent.SPR4-peptide alters bone metabolism of normal and HYP mice.Glucocorticoid dose determines osteocyte cell fate.Biomineralization of bone: a fresh view of the roles of non-collagenous proteins.Phosphatonins: new hormones involved in numerous inherited bone disordersAge dependent regulation of bone-mass and renal function by the MEPE ASARM-motifPhosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activitySclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.Differential stem- and progenitor-cell trafficking by prostaglandin E2.Endocrine functions of bone in mineral metabolism regulation.Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis.Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.Phosphorylated proteins and control over apatite nucleation, crystal growth, and inhibition.Novel regulators of Fgf23 expression and mineralization in Hyp boneBiological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach.Role of cathepsin D in U18666A-induced neuronal cell death: potential implication in Niemann-Pick type C disease pathogenesis.
P2860
Q24632241-F87FE246-32F0-4B85-AE07-7326272D3220Q24648401-22185081-C15C-46F9-917A-EB7567AAE4B1Q27026805-AC7FE080-1D88-48BA-BFD4-5806248681C9Q27690863-F57139DD-A75B-4B4B-B6B3-2698CB7D4356Q28275381-FE0D1714-2524-47EC-84E4-181448FCB796Q28301682-08E2B65A-75B0-429B-9CA1-028E6A391E45Q28593877-3CEF36F1-03F4-47DE-8AC1-3CF0BDA6CC82Q31161423-9470D96E-1499-49A5-80D6-254E71FE7E49Q33617326-BD82D536-C612-4C7F-9702-53093B004C62Q33643995-D2873CE2-73D5-4313-8AC5-3427583DF0A8Q33684986-FFF94153-D2E0-4D38-AC9A-3639EFA5AECDQ35105384-AB802059-5A01-4DB4-A75E-F4C4F97AA713Q35118585-69B8504A-523E-4544-853F-4820141FBEE2Q35128414-0E658205-2A5D-4481-9AD1-87B7448699ABQ35225093-BFE64A97-85F0-437D-A523-67B76527448AQ35606605-61170262-510D-4C34-996A-8A124D132284Q35755676-75A964D3-F68F-4563-A40B-257C74F233AAQ35850452-0B99CA07-95CF-4132-B847-1028D13DA6E6Q35975746-7C645AEA-E2DE-4841-AAD5-E3C5B1D0EDE7Q35983181-EDF55222-6D19-4B2A-BFAD-92E8D5384045Q36074718-BC208E1F-E725-4929-AA6A-CA0170BC5FDFQ36367168-D5551BFF-A133-46D6-A51B-C93C5099AEDCQ36711496-46B1221D-72F1-4C97-B07C-2914B13F1A86Q36982323-9FD0A0D8-A91D-4D48-93DF-D2B65E0A16D0Q37014020-2D41E501-FE04-42FF-B250-4B9C0134A9E8Q37106569-1317ECB4-79C7-4C38-811B-6D6A7DA807B2Q37285119-9038E79C-14D6-4272-96D4-1BAC0505A676Q37332408-5DE47B28-97EA-48BC-B406-6793281CA23AQ39202192-6FD262CF-8ABC-4F34-A214-D09308929AD2Q43118769-0612F03B-7A37-4C4F-9BB8-5403663A956E
P2860
Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@ast
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@en
type
label
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@ast
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@en
prefLabel
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@ast
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@en
P2093
P2860
P1433
P1476
Correction of the mineralizati ...... inhibitors CA074 and pepstatin
@en
P2093
Jeannine Oconnor
Jody Harrison
Martine P Roudier
Naoko Matsumoto
Norimoto Yanagawa
Peter S N Rowe
Remi N J Shih
Shiguang Liu
Steve Bain
P2860
P304
P356
10.1016/J.BONE.2006.04.012
P577
2006-06-09T00:00:00Z